Poor choice of primary outcome in a clinical trial of pirfenidone in patients with IPF [2]

American Journal of Respiratory and Critical Care Medicine

Volumn 172, Issue 9, 2005, Pages 1228-1229

  Levitt, Joseph ^a   Gould, Michael K ^b  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OXYHEMOGLOBIN; PIRFENIDONE;

ARTERIAL OXYGEN SATURATION; CLINICAL TRIAL; DRUG EFFICACY; EXERCISE TEST; FIBROSING ALVEOLITIS; HUMAN; LETTER; LUNG FIBROSIS; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TREADMILL; TREATMENT OUTCOME;

EID: 30344436397     PISSN: 1073449X     EISSN: 1073449X     Source Type: Journal    
DOI: 10.1164/ajrccm.172.9.951     Document Type: Letter

References (3)

1. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, Taguchi Y, Nagai S, Itoh H, Ohi M, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005;171:1040-1047.
2. Eaton T, Young P, Milne D, Wells AU. Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005;171:1150-1157.
3. Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, King TE Jr. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.N Engl JMed 2004;350:125-133.